FDA Approves First mRNA Flu Vaccine for Adults 50 and Older

The U.S. Food and Drug Administration (FDA) has approved mFLUSIVA, the first mRNA vaccine for influenza, specifically for adults aged 50 and older. Clinical trials demonstrated that this new vaccine is more effective than traditional flu shots, with one study reporting 27% fewer flu cases in vaccinated individuals. This approval marks a significant advancement in flu prevention technology.